CV-8972 Form A Crystal Stability for Cardiac Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart disease, such as heart failure, ischemic heart disease, and diabetic cardiomyopathies, are limited by the predominance of fatty acid oxidation in cardiac mitochondria, leading to reduced cardiac efficiency.
Innovation Solution
The development of crystallographic forms of CV-8972, particularly Form A, which is the most stable under ambient conditions, for use in pharmaceutical compositions that can be effectively stored and distributed without loss of therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple polymorphic forms of CV-8972 are used in pharmaceutical compositions, then the therapeutic efficacy may vary, but the stability and reliability of the composition during storage and distribution deteriorate
Solution Approach 1:
The patent identifies and characterizes five distinct polymorphic forms (A, B, C, D, E) of CV-8972, each with unique crystal structures and stability properties. By changing the polymorphic form parameter, the patent achieves both therapeutic efficacy (all forms are pharmaceutically active) and storage stability (Form A is most stable under ambient conditions). This parameter change approach allows selection of the optimal polymorph for specific application requirements.
Solution Approach 2:
The patent segments the single compound CV-8972 into multiple distinct polymorphic forms with different properties. Each polymorph represents a discrete segment with its own stability characteristics, allowing the selection of Form A for storage and distribution scenarios where stability is paramount, while other forms may be used when different therapeutic or physical properties are desired.
2Stability of the object's composition
If Form A crystals of CV-8972 are used in pharmaceutical compositions, then the stability under ambient conditions is improved, but the complexity of identifying and characterizing the correct polymorph increases
Solution Approach 1:
The patent performs preliminary identification and characterization of all five polymorphic forms before pharmaceutical composition development. By预先 establishing the stability hierarchy and properties of each form, the patent eliminates the need for complex real-time polymorph identification during storage and distribution. The preliminary work includes X-ray diffraction patterns, thermal analysis, and stability testing for each form.
Solution Approach 2:
The patent replaces complex mechanical or physical methods of polymorph identification with spectroscopic and diffractometric techniques. Specifically, X-ray powder diffraction (XRPD) patterns serve as unique fingerprints for each polymorph, allowing rapid and unambiguous identification without complex mechanical analysis. This substitution simplifies the characterization process while maintaining accuracy.
3Adaptability or versatility
If polymorphic forms other than Form A are used, then different physical or chemical properties may be achieved, but the loss of therapeutic efficacy during storage increases
Solution Approach 1:
The patent provides beforehand cushioning by selecting Form A, the most stable polymorph, for pharmaceutical compositions intended for long-term storage and distribution. This preliminary selection prevents potential transformation to less stable forms that could lead to loss of therapeutic efficacy. The patent acknowledges that other polymorphs may offer different properties but cushions against efficacy loss by recommending Form A for applications where stability is critical.
Data Source
AI summary
The invention provides polymorphs of a compound of Formula (X):The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.